Professional Documents
Culture Documents
Lot Number: 1
Release Category: D
Description: Contains the 5.5 kb HincII-EcoRI fragment from pLG339, which in turn contains the
pSC101 ori and a kanamycin resistance gene. Also contains a 245 bp FspI-EcoRI
fragment with the pSPORT multiple cloning site.
Plasmid Map
Special Low copy number, 5820 bp plasmid vector useful in stabilizing lentivirus sequences
Characteristics: such as SIV, EIAV, Visna maedi, etc. for subcloning, propagation, and manipulation in
E. coli. Reduces the level of toxic gene expression from cryptic promoter sequences.
Recommended -70°C
Storage:
References: Cunningham TP, Montelaro RC, Rushlow KE. Lentivirus envelope sequences and
proviral genes are stabilized in Escherichia coli when cloned in low copy number
plasmid vectors. Gene 124:93-98, 1993.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cloning Vector
(pLG339/SPORT) from Dr. Ronald C. Montelaro (cat# 3924)." Also include the
reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Lot Number: 1
Release Category: D
Description: Contains the 3.05 kb PvuII-HincII fragment from pLG338, which in turn contains the
pSC101 ori. Also contains a 1.65 bp EcoRI-HaeII fragment with the pBR322 ampicillin
resistance gene, and the multiple cloning site (FspI-EcoRI) from pIBI30.
Plasmid Map
Special Low copy number, 5215 bp plasmid vector useful in stabilizing lentivirus sequences
Characteristics: such as SIV, EIAV, Visna maedi, etc. for subcloning, propagation, and manipulation in
E. coli. Reduces the level of toxic gene expression from cryptic promoter sequences.
GenBank Accession no. AF035682.
Recommended -70°C
Storage:
References: Cunningham TP, Montelaro RC, Rushlow KE. Lentivirus envelope sequences and
proviral genes are stabilized in Escherichia coli when cloned in low copy number
plasmid vectors. Gene 124:93?98, 1993.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cloning Vector
(pLG338/30) from Dr. Ronald C. Montelaro (cat# 3923)." Also include the reference
cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: B
Provided: 1 ml transformed DH5α (glycerol stocks). The plasmid carries a ColE1 origin, and a
ß-lactamase cassette. Growth in luria broth + 50 µg/ml ampicillin is recommended.
Description: This is an empty vector which has been utilized in DNA vaccines. Expression is driven by
the CMV IE promoter (Towne isolate). The sequence has been mapped and is provided.
Cloning Vector: The cloning vector is pJW4304. The size of the cloning vector is 5132 bp.
Special This clone is unique due to the high level of expression upon transfection into
Characteristics: mammalian cells in vivo.
Recommended -70°C.
Storage:
References: Mossman SP, Bex F, Berglund P, Arthos J, O'Neil SP, Riley D, Maul DH, Bruck C, Momin
P, Burny A, Fultz PN, Mullins JI, Liljestrom P, Hoover EA. Protection against lethal simian
immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus
gp160 vaccine and by a gp120 subunit vaccine. J Virol 70:1953-1960, 1996.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pJW4304 from
Drs. James Arthos, Laura Heath and James Mullins (cat# 7622)." Also include the
references cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: E
Ampicillin resistant
The sequence maps to partial LTR and gag sequences of the HTLV-II virus (isolate
G12) between nucleotides 39 and 840 corresponding to partial LTR and gag sequences
of the virus.
This sequence can serve as a positive control in population screenings using the
following primers:
Forward: 5'-CGAGTCATCGACCCAAAAGGTC-3'
Reverse: 5'-GGAGTTGGGGAAAGCCCGTGG-3'
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for
reconstitution of dried DNA reagents. Dried DNA Notice
Plasmids can be propagated in STBL2 cells and grown at 37°C. Larger plasmids may
benefit from growth at 30°C. This construct may also be grown in other competent
cells.
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
References: Oltra, E., Garcia-Escudero, M., Mena-Duran, A. V., Monsalve, V., & Cerda-Olmedo, G.
(2013). Lack of evidence for retroviral infections formerly related to chronic fatigue in
Spanish fibromyalgia patients. Virol J, 10, 332. doi: 10.1186/1743-422X-10-332
PUBMED
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HTLV-II Cloning
Vector (pGEMT-HTLV-2) from Dr. Elisa Oltra." Also include the references cited above
in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pTY-EFeGFP
Release Category: C
Description: Lentiviral transducing vector containing the EF1a promoter-driven eGFP gene.
Special Self-inactivated lentiviral vector (pTY) expressing the eGFP reporter gene. Reporter
Characteristics: gene expression can be detected directly by flow cytometry.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for
reconstitution of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture
Storage: barrier bag.
References: Chang L-J, Urlacher V, Iwakuma T, Cui Y, Zucali J. Efficacy and safety analyses of a
recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther
6:715–728, 1999.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH:pTY-EFeGFP
from Dr. Lung-Ji Chang." Also include the references cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pHP-dl-N/A
Release Category: C
Description: Derived from the lentiviral packaging vector pHP-1dl.28 (see attached figure) with an
additional 695 bp env deletion (NdeI-AseI).
From Chang L-J, et al. Gene Ther 6:715, 1999 (Figure 1a).
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
References: Chang L-J, Urlacher V, Iwakuma T, Cui Y, Zucali J. Efficacy and safety analysis of a
recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther
6:715-728, 1999.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pHP-dl-N/A from
Dr. Lung-Ji Chang." Also include the reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pTY-EFnlacZ
Release Category: C
Description: Lentiviral transducing vector containing the EF1a promoter-driven nuclear localized lacZ
gene.
Plasmid Map
Special Self-inactivated lentiviral vector (pTY) expressing the nlacZ reporter gene.
Characteristics:
Sequence file lot 051159
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pTY-EFnlacZ from
Dr. Lung-Ji Chang (cat# 4694)." Also include the references cited above in any
publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pCEP4-Tat
Release Category: C
Description: This is a HIV-1 SF-2 Tat eukaryotic expression plasmid with the preferred eukaryotic
translational initiation codon (-CCACC-ATG).
Special This construct is 9922 bp including the insert and contains the HIV-1 SF2 Tat gene
Characteristics: from pSP72-tat ligated to pCEP4 (XhoI-BglII site). It contains a selectable hygromycin
resistance marker. Efficiently transactivates HIV-1 LTR.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for
reconstitution of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture
Storage: barrier bag.
References: Chang L-J, Urlacher V, Iwakuma T, Cui Y, Zucali J. Efficacy and safety analyses of a
recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther
6:715?728, 1999.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pTY-Linker
Release C
Category:
Description: Generated by combining the lentiviral transducing vector pTV, self-inactivating lentiviral
vector pTYΔCT-CMVnlacZdl3'U3#1U5pA (see attached figure) and 5' splice site and env
deletion env.dl.6 (see attached figure) with a NotI-EcoRI linker. Unique cloning sites on
the linker that can be used for foreign gene insertion are: NotI, NheI, SalI, SmaI, BamHI,
SacII, SpeI, EcoRI, and KpnI.
Special Universal lentiviral self-inactivated transducing vector. Contains a chimeric 5' CMV-TATA
Characteristics: enhancer/promoter site and a 3' bovine growth hormone polyA signal. The backbone is
derived from pUC18 (of pNL4-3). This HIV-1 derived transducing vector contains the
following HIV sequences; RU5, UTR without the major splice site, 720 bp gag, 927 bp env
including the RRE, the two integration att sites and the 3'R.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
Plasmids can be propagated in STBL2 cells and grown at 37°C. Larger plasmids may
benefit from growth at 30°C. This construct may also be grown in other competent cells.
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
References: Chang L-J, Urlacher V, Iwakuma T, Cui Y, Zucali J. Efficacy and safety analyses of a
recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther
6:715-728, 1999. Iwakuma T, Cui Y, Chang L-J. Self-inactivating lentiviral vectors with
U3 and U5 mutations. Virology 261:120-132, 1999. Cui Y, Iwakuma T, Chang L-J.
Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function.
J Virol 73:6171-6176, 1999.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pTY-Linker from
Dr. Lung-Ji Chang." Also include the references cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: HIV-gpt
Catalog 1067
Number:
Release A
Category:
Description: An XbaI-HpaI pHXB2gpt fragment (Drs. A. Fisher and F. Wong-Staal) containing proviral
and flanking cellular sequences was cloned into the HincII-XbaI site of pBS KS (+/-). A 1.2
KB NdeI-BglII fragment (nt 6402-7620) was deleted from env gene, and the 1.1 kb
PvuII-DraI SV2gpt fragment (Dr. M. Mulligan) was inserted at the env deletion site.
Contains intact HXB2 rev and tat genes. Replication-defective.
Description of Contains intact HIV-1 HXB2 rev and tat genes. Deletion of sequences encoding gp160 has
Clone: rendered HIV-gpt replication-defective. The PvuII - DraI SV2gpt fragment contains the
SV40 origin of replication and coding sequences for the gpt gene.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Cloning Strategy: An XbaI - HpaI fragment from pHXB2gpt containing HIV-1 proviral and
flanking cellular sequences was cloned into the HincII - XbaI site of pBS. A 1.2 kb NdeI -
BglII fragment (nt 6402-7620) was deleted from env gene, and the 1.1 kb PvuII - DraI
SV2gpt fragment was inserted at the env deletion site.
Source Of Pro Virus: HIV-1 plasmid pHXB2gpt (Dr. A. Fisher and Dr. F. Wong-Staal) and
pSV2gpt (Dr. M. Mulligan).
This reagent is currently being provided as dried purified DNA stabilized in DNAstable PLUS.
Please see the notice for additional information and the protocol for reconstitution of dried
DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier bag.
Storage:
References: Page KA, Landau NR, Littman DR. Construction and use of a Human immunodeficiency virus
vector for analysis of virus infectivity. J Virol 64:5270-5276, 1990.
NOTE: Acknowledgment for publications should read "The following reagent was obtained through
the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-gpt from Dr. Kathleen
Page and Dr. Dan Littman." Also include the reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pSV-Ψ-MLV-env-
Release Category: C
Description: Ψ-Moloney Murine Leukemia virus DNA (from Richard Mann) was cloned into the SV40
expression vector pSV7d at the EcoRI site. Restriction sites in the MLV sequence can be
found in the Appendix to Volume 2 of the Cold Spring Harbor Tumor Virus Book. The
mouse flanking sequences present on either side of the provirus have not been
sequenced.
Ampicillin resistant
Plasmids can be propagated in STBL2 cells and grown at 37°C. Larger plasmids may
benefit from growth at 30°C. This construct may also be grown in other competent
cells.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
Contributor: Dr. Nathaniel Landau, Aaron Diamond AIDS Research Center, the Rockefeller University.
References: Landau NR, Littman DR. packaging system for rapid production of murine leukemia virus
vectors with variable tropism. J Virol 66:5110-5113, 1992.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pSV-Ψ-MLV-env-
from Dr. Nathaniel Landau (cat# 3422)." Also include the reference cited above in any
publications. Patent pending.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pSV-A-MLV-env
Release Category: A
Provided: 10 μg of dried purified DNA stabilized in DNAstable PLUS
Description: Contains the amphotropic murine leukemia virus env gene linked to the MLV LTR, and
an SV40 origin. The cloning vector is pSV7d.
Description of Contains the amphotropic murine leukemia virus env gene linked to the MLV LTR. The
Clone: plasmid also contains the SV40 origin. Ampicillin resistant.
Special This construct is 5734 bp including the insert.
Characteristics:
Co-transfection of COS cells with SV-A-MLV-env and HIV-gpt (catalog #1067) yields
an HIV/MLV (amphotropic) pseudotype virus.
Contributor provided plasmid map
Plasmid map and sequence file lot 110151
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for
reconstitution of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture
Storage: barrier bag.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
REV: 10/20/2019 Page 1 of 2
Contributor: Dr. Nathaniel Landau and Dr. Dan Littman
References: Landau NR, Page KA, Littman DR. Pseudotyping with human T-cell leukemia virus type
I broadens the human immunodeficiency virus host range. J Virol 65:162-169, 1991.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: SV-A-MLV-env
from Dr. Nathaniel Landau and Dr. Dan Littman." Also include the reference cited
above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
REV: 10/20/2019 Page 2 of 2
Packaging and Helper Constructs >> Other
DATA SHEET
Release Category: C
Description: The plasmid encodes for the Gag/Pro/Pol genes derived from HIV-1. The promoter is
the chicken beta actin promoter and polyAdenylation signal is the rabbit beta globin
polyA. Resistance to Ampicillin.
Cloning Vector: The size of the cloning vector including the insert is 10703 bp.
Cloning Site: The size of the insert is 8100 bp from the CMV enhancer to the polyA signal.
Special Vector is a second generation packaging plasmid used to produce HIV-1 derived
Characteristics: lentivectors. Replaces plasmids pCMVdeltaR8.91 and pCMVdeltaR8.74.
Plasmid Map
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for
reconstitution of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture
Storage: barrier bag.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Lot Number: 2
Release Category: A
Provided: The plasmids are supplied as a complete collection of transformed bacterial stocks in a
single 96-well plate.
Description: Two sets of 26 substitution mutants extending from the 5' LTR (-453 bp from the
transcription start site) to base +15. Each mutant replaces 18 bp of the wild type HXB2
sequence with an NdeI-XhoI-SalI (NXS) polylinker (CATATGCTCGAGGTCGAC).
Click here to see the Plate A Well Assignment for this reagent.
Special The 96 well plates used for expansion have a 1.5ml capacity. Each of the wells to be
Characteristics: inoculated were filled with 1ml of LB+ ampicillin at 100µg/ml.
The plates were inoculated by using a pin inoculator configured for 96 well plates. The
inoculator was dipped in ethanol and flamed before and after each use. The expansion
plates were place in a 37°C incubator overnight. The following morning growth was
observed in all wells. Sterile glycerol (110µl) was added to each well and mixed
thoroughly.
A mixture of broth culture and glycerol was aliquoted into U bottom 96 well plates.
Plates were aliquoted at 100µl per well, covered with sterile sealing material and
labeled on top cover. All plates stored at -80°C.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pΔκB-HIV-CAT
Release Category: A
Description: Contains a 727 bp HindIII-XhoI insert encoding the HIV-1 LTR with mutated kB
sequences linked to the CAT gene.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for
reconstitution of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture
Storage: barrier bag.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Catalog 1520
Number:
Release C
Category:
Description: The 5' end of the LTR to position -48 from the transcriptional start site is deleted, but the
presence of the NF-kB enhancer sequence (reverse) resulted in restored transcriptional
activity (CAT assay).
Clone pC15CAT was cleaved with KpnI, treated with Bal31 exonuclease, blunted and the
XbaI linkers ligated. The resultant deletion mutant, pCD54E8, contains HIV-1 IIIB LTR
sequences from -48 to +80 located in front of the CAT gene. The NFκB sequence has been
cloned into the XbaI site at -48 in the reversed orientation. The NFκB insert sequence is:
XbaI XbaI -48 5'cgcagcgagtcact/ctagatggaaagtccccagcggaaagtccct/ctagag*gcgag3'
Special The 5' end of the LTR to position -48 from the transcriptional start site is deleted, but the
Characteristics: presence of the NFκB enhancer sequence resulted in restored transcriptional activity as
determined by CAT assay. The LTR sequences are cloned upstream to the CAT gene.
Recommended -70degreeC
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Arya SK, Guo C, Josephs SF, and Wong-Staal F. Trans-activator gene of human
T-lymphotropic virus type III (HTLV-III). Science 9:69-73, 1985.
Chang KS, Liu WT, Josephs SF. Regulation of cellular trans-activating activities in two
different promonocytic leukemia cell lines. Cancer Lett 60:75-83, 1991.
Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O'Brien SJ, Wong-Staal F.
Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a viral
sequence encoding 58 amino acids and lacks tissue specificity. Virology 148:226-231.
NOTE: Acknowledgment for publications should read "The following reagent was obtained through
the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR CAT Reporter
Vector (pCD54E8)from Dr. Steven Josephs (cat# 1520)." Also include the references cited
above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Description: The 5' end of the LTR to position -103 from the transcriptional start site is deleted.
Special Clone pC15CAT was cleaved with KpnI, treated with Bal31 exonuclease, blunted and the
Characteristics: XbaI linkers ligated. The resultant deletion mutant, pCD38, contains HIV-1IIIB LTR
sequences from -103 to +80 located in front of the CAT gene. The 5' end of the LTR to
position -103 from the transcriptional start site is deleted.
Bacterial Host: E. coli DH5-a. Also grows in HB101.
Recommended -70°C
Storage:
References: Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express
chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2:1044-1051, 1982.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Chang KS, Liu WT, Josephs SF. Regulation of cellular trans-activating activities in two
different promonocytic leukemia cell lines. Cancer Lett 60:75-83, 1991.
Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O'Brien SJ, Wong-Staal
F. Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a
viral sequence encoding 58 amino acids and lacks tissue specificity. Virology
148:226-231.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR CAT
Reporter Vector (pCD38) from Dr. Steven Josephs (cat# 1519)."Also include the
reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Description: The 5' end of the LTR to position -48 from the transcriptional start site is deleted, but
the presence of the NF-kB enhancer sequence (forward) resulted in restored
transcriptional activity as determined by CAT assay. The LTR sequences are cloned
upstream to the CAT gene.
,br /> Clone pC15CAT was cleaved with KpnI, treated with Bal31 exonuclease, blunted
and the XbaI linkers ligated. The resultant deletion mutant, pCD54E9, contains
HIV-1IIIB LTR sequences from -48 to +80 located in front of the CAT gene. The NFκB
sequence has been cloned into the XbaI site at -48 in the forward orientation.
Special The 5' end of the LTR to position -48 from the transcriptional start site is deleted, but
Characteristics: the presence of the NFκB enhancer sequence resulted in restored transcriptional activity
as determined by CAT assay. The LTR sequences are cloned upstream to the CAT gene.
Recommended -70°C
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Chang KS, Liu WT, Josephs SF. Regulation of cellular trans-activating activities in two
different promonocytic leukemia cell lines. Cancer Lett 60:75-83, 1991.
Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O'Brien SJ, Wong-Staal
F. Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a
viral sequence encoding 58 amino acids and lacks tissue specificity. Virology
148:226-231.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR CAT
Reporter Vector (pCD54E9) from Dr. Steven Josephs (cat# 1521)." Also include the
reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Description: The nef region is deleted from the HIV LTR at -117. NF-kB and Sp-1 nuclear factor
binding sites and the TAR region are retained.
Clone pC15CAT was cleaved with KpnI, then treated with Bal31 exonuclease, blunted
and the XbaI linkers ligated. The resultant deletion mutant, pCD23, contains HIV-1IIIB
LTR sequences from -117 to +80 located in front of the CAT gene.
Special The nef region is deleted from the HIV LTR. The clone retains NFκB and Sp-1 nuclear
Characteristics: factor binding sites and the TAR region.
Recommended -70°C
Storage:
References: Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express
chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2:1044-1051, 1982.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Chang KS, Liu WT, Josephs SF. Regulation of cellular trans-activating activities in two
different promonocytic leukemia cell lines. Cancer Lett 60:75-83, 1991.
Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O'Brien SJ, Wong-Staal
F. Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a
viral sequence encoding 58 amino acids and lacks tissue specificity. Virology
148:226-231.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pCD23 from Dr.
Steven Josephs." Also include the reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Description: The 5' end of the HIV LTR to position -176 from the transcriptional start site is deleted.
Clone pC15CAT was cleaved with KpnI, then treated with Bal31 exonuclease, blunted
and the XbaI linkers ligated. The resultant deletion mutant, pCD16, contains HIV-1IIIB
LTR sequences from -176 to +80 located in front of the CAT gene.
Special The 5' end of the HIV LTR to position -176 from the transcriptional start site is deleted.
Characteristics:
Recommended -70°C
Storage:
References: Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express
chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2:1044-1051, 1982.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Chang KS, Liu WT, Josephs SF. Regulation of cellular trans-activating activities in two
different promonocytic leukemia cell lines. Cancer Lett 60:75-83, 1991.
Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O'Brien SJ, Wong-Staal
F. Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a
viral sequence encoding 58 amino acids and lacks tissue specificity. Virology
148:226-231.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR CAT
Reporter Vector (pCD16) from Dr. Steven Josephs (cat# 1523)." Also include the
reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Description: Deletion at -670D (CAT gene KpnI site). LTR-directed gene expression is enhanced
compared to that of the full-length LTR.
Clone pC15CAT was cleaved with KpnI, treated with Bal31 exonuclease, blunted and the
XbaI linkers ligated. Clone pCD12 contains a small deletion in the CAT gene KpnI site.
Special LTR-directed gene expression is enhanced compared to that of the full-length LTR.
Characteristics:
Recommended -70°C
Storage:
References: Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express
chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2:1044-1051, 1982.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Chang KS, Liu WT, Josephs SF. Regulation of cellular trans-activating activities in two
different promonocytic leukemia cell lines. Cancer Lett 60:75-83, 1991.
Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O'Brien SJ, Wong-Staal
F. Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a
viral sequence encoding 58 amino acids and lacks tissue specificity. Virology
148:226-231.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR CAT
Reporter Vector (pCD12) from Dr. Steven Josephs (cat# 1524)." Also include the
reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Description: The nef region, NF-kB and Sp-1 nuclear factor binding sites are deleted at -48.
Clone pC15CAT was cleaved with KpnI, then treated with Bal31 exonuclease, blunted
and the XbaI linkers ligated. The resultant deletion mutant, pCD54 contains HIV-1 IIIB
LTR sequences from -48 to +80 located in front of the CAT gene.
Special The nef region is deleted from the HIV LTR. The NFκB and Sp-1 nuclear factor binding
Characteristics: sites are also deleted.
Recommended -70°C
Storage:
References: Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express
chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2:1044-1051, 1982.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Chang KS, Liu WT, Josephs SF. Regulation of cellular trans-activating activities in two
different promonocytic leukemia cell lines. Cancer Lett 60:75-83, 1991.
Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O'Brien SJ, Wong-Staal
F. Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a
viral sequence encoding 58 amino acids and lacks tissue specificity. Virology
148:226-231.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR CAT
Reporter Vector (pCD54) from Dr. Steven Josephs (cat# 1525)." Also include the
reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Description: The 5' end of the LTR to position -278 from the transcriptional start site is deleted.
Clone pC15CAT was cleaved with KpnI, treated with Bal31 exonuclease, blunted and the
XbaI linkers ligated. The resultant deletion mutant, pCD7, contains HIV-1IIIB LTR
sequences from -278 to +80 located in front of the CAT gene.
Special The 5' end of the LTR to position -278 from the transcriptional start site is deleted.
Characteristics:
Recommended -70°C
Storage:
References: Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express
chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2:1044-1051, 1982.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Chang KS, Liu WT, Josephs SF. Regulation of cellular trans-activating activities in two
different promonocytic leukemia cell lines. Cancer Lett 60:75-83, 1991.
Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O'Brien SJ, Wong-Staal
F. Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a
viral sequence encoding 58 amino acids and lacks tissue specificity. Virology
148:226-231.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program,Division of AIDS, NIAID, NIH: HIV-1 LTR CAT
Reporter Vector (pCD7) from Dr. Steven Josephs (cat# 1526)." Also include the
reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Clone pC15CAT contains the HIV-1 LTR cloned into the HindIII site of plasmid pSV0CAT.
Ampicillin resistant
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Chang KS, Liu WT, Josephs SF. Regulation of cellular trans-activating activities in two
different promonocytic leukemia cell lines. Cancer Lett 60:75-83, 1991.
Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O'Brien SJ, Wong-Staal
F. Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a
viral sequence encoding 58 amino acids and lacks tissue specificity. Virology
148:226-231.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR CAT
Reporter Vector (pC15CAT) from Dr. Steven Josephs (cat# 1527)."Also include the
reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Description: The nef region and NF-kB binding site are deleted at -65, but the two Sp-1 nuclear
factor binding sites remain.
Clone pC15CAT was cleaved with KpnI, then treated with Bal31 exonuclease, blunted
and the XbaI linkers ligated. The resultant deletion mutant, pCD52 contains HIV-1 IIIB
LTR sequences from -65 to +80 located in front of the CAT gene.
Special The nef region is deleted from the HIV LTR. The NFκB binding site is also deleted, but
Characteristics: the clone retains two Sp-1 nuclear factor binding sites.
Recommended -70degreeC.
Storage:
References: Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express
chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2:1044-1051,
1982.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Chang KS, Liu WT, Josephs SF. Regulation of cellular trans-activating activities in two
different promonocytic leukemia cell lines. Cancer Lett 60:75-83, 1991.
Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O'Brien SJ,
Wong-Staal F. Transactivation induced by human T-lymphotropic virus type III (HTLV
III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity.
Virology 148:226-231.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR CAT
Reporter Vector (pCD52) from Dr. Steven Josephs (cat# 1528)."
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: A
Description: Contains a 727 bp dIII-XhoI insert encoding the HIV-1 LTR with normal NF-κB
sequences linked to the CAT gene.
Plasmid Map
Special This clone serves as a positive control for pΔκB-HIV-CAT (Catalog #2618). Mutant κB
Characteristics: HIV VAT contours alterations in both κB sites (GGGACTTTCC->TCTACTTTCC).
Recommended -70°C
Storage:
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR CAT
Reporter Vector (pHIV-CAT) from Dr. Gary Nabel and Dr. Neil Perkins (cat# 2619)."
Also include the reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: D
Description: An XhoI-HindIII fragment (approximately 720 base pairs) of HIV-1 cDNA clone C15
containing the U3 and R regions of the 3' LTR was cloned 5' to the CAT gene of pSV2CAT.
Cloning Vector: pSV2CAT (Gorman, C.M., et al. Mol. Cell. Biol. 2:1044, 1982).
Description of XhoI-HindIII fragment (~720 base pairs) of HIV-1 cDNA clone C15 containing the U3
Clone: and R regions of the 3' LTR was cloned 5' to the chloramphenicol acetyltransferase (CAT)
gene.
Special This plasmid will direct the expression of CAT under control of the HIV-1 LTR sequences
Characteristics: that are responsive to Tat.
Plasmid Map
Recommended -70°C.
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR CAT
Reporter Vector (pU3R-III CAT) from Dr. Joseph Sodroski (cat# 330)." Also include the
references cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Catalog 2135
Number:
Release C
Category:
Description: A synthetic 26 bp oligonucleotide containing the a subunit of the IL-2 receptor (IL-2Ra)
NFκB binding site (region -268 through -243) with a 3 bp mutation was cloned into the
SalI site of plasmid Δ56.
Recommended -70°C.
Storage:
References: Pierce JW, Lenardo M, Baltimore D. Oligonucleotide that binds nuclear factor NF-κB acts as
a lymphoid-specific and inducible enhancer element. Proc Natl Acad Sci USA
85:1482-1486, 1988. Gilman MZ, Wilson RN, Weinberg RA. Multiple protein-binding sites
in the 5'-flanking region regulate c-fos expression. Mol Cell Biol 6:4305-4316, 1986.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Catalog 2134
Number:
Release C
Category:
Description: A synthetic 26 bp oligonucleotide containing the alpha subunit of the IL-2 receptor (IL-2Ra)
NF-kB binding site (-268 through -243) was cloned into the SalI site of plasmid delta56.
Recommended -70°C
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
NOTE: Acknowledgment for publications should read "The following reagent was obtained through
the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: CAT Reporter Vector
(pIL-2r) from Dr. Michael Lenardo (cat# 2134)." Also include the references cited above in
any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Description of Contains two copies of the κ light chain enhancer NF-κB site (B orientation) cloned into
Clone: the SalI site of Δ56.
Special Double digestion of the plasmid with EcoRI and HindIII produces a 500 kb fragment
Characteristics: containing the insert, a 2650 kb fragment, and a 2130 kb fragment. Digestion with
HincII produces a 1750 kb fragment containing the insert, and 2900, 370, and 240 kb
fragments.
Bacterial Host: DH5α.
Recommended -70°C.
Storage:
References: Gilman MZ, Wilson RN, Weinberg RA. Multiple protein-binding sites in the 5'-flanking
region regulate c-fos expression. Mol Cell Biol 6:4305-4316, 1986.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Contains two mutated copies (3937-3958 GGGG-→ATTC) of the κ light chain enhancer NF--κB site
(B orientation) cloned into the SalI site of -κ56.
Special Double digestion of the plasmid with EcoRI and HindIII produces a 500 kb fragment
Characteristics: containing the insert, a 2650 kb fragment, and a 2130 -κb fragment. Digestion with
HincII produces a 1750 -κb fragment containing the insert, and 2900, 370, and 240 -κb
fragments. CAT activity is substantially reduced in comparison to pJ16 (Cat. #2136).
Bacterial Host: DH5-α.
Recommended -70°C.
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: CAT Reporter
Vector (pJ32) from Dr. Jacqueline Pierce and Dr. Michael Lenardo (cat# 2137)." Also
include the reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Ampicillin resistant
This construct can be used for measuring viral replication in pseudotyped single-round
infection assays using GFP as the output reading. It can also be used to quantitatively
measure HIV-1 drug resistance by replacing the gag-pol region of the construct with a
desired sequence at the ApaI/AgeI site.
A restriction digest with ApaI and AgeI produces fragments of approximately 13200 bp
and 1500 bp.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Plasmids can be propagated in STBL2 cells and grown at 37°C. Larger plasmids may
benefit from growth at 30°C.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
Plus. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 NL4-3
ΔEnv EGFP Reporter Vector from Drs. Haili Zhang, Yan Zhou, and Robert Siliciano (cat#
11100)." Also include the reference cited above in any publications.
Patent Pending.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pLTR.D24-SEAP-IRES-EGFP
Catalog 11788
Number:
Release C
Category:
Cloning Site: The full-length LTRs were cloned directionally between MluI and NheI sites.
Special Two independent reporter genes secreted alkaline phosphatase and green fluorescent
Characteristics: protein are simultaneously expressed from these vectors in Tat-responsive manner. The
LTRs have important differences in their transcription factor binding sites and will be
useful in viral transactivation studies, and in the screening of viral inhibitors. The
expression of both of the reporter genes could be monitored without terminating the assay.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
References: Siddappa NB et al., AIDS Research and Human Retroviruses, 23(10), 1268-1278, 2007.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH:
pLTRD24-SEAP-IRES-EGFP from Dr. Udaykumar Ranga.”Also include the reference cited
above in any publications. Contact the contributor for more details.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pLTR.A5/2000-SEAP-IRES-EGFP
Catalog 11789
Number:
Release C
Category:
Cloning Site: The full-length LTRs were cloned directionally between MluI and NheI sites.
Special Two independent reporter genes secreted alkaline phosphatase and green fluorescent
Characteristics: protein are simultaneously expressed from these vectors in Tat-responsive manner. The
LTRs have important differences in their transcription factor binding sites and will be
useful in viral transactivation studies, and in the screening of viral inhibitors. The
expression of both of the reporter genes could be monitored without terminating the assay.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
References: Siddappa NB et al., AIDS Research and Human Retroviruses, 23(10), 1268-1278, 2007.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH:
pLTR.A5/2000-SEAP-IRES-EGFP from Dr. Udaykumar Ranga.”Also include the reference
cited above in any publications. Contact the contributor for more details.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pLTR.SB253-SEAP-IRES-EGFP
Catalog 11790
Number:
Release C
Category:
Cloning Site: The full-length LTRs were cloned directionally between MluI and NheI sites.
Special Two independent reporter genes secreted alkaline phosphatase and green fluorescent
Characteristics: protein are simultaneously expressed from these vectors in Tat-responsive manner. The
LTRs have important differences in their transcription factor binding sites and will be
useful in viral transactivation studies, and in the screening of viral inhibitors. The
expression of both of the reporter genes could be monitored without terminating the assay.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
References: Siddappa NB et al., AIDS Research and Human Retroviruses, 23(10), 1268-1278, 2007.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH:
pLTR.SB253-SEAP-IRES-EGFP from Dr. Udaykumar Ranga.”Also include the reference
cited above in any publications. Contact the contributor for more details.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: D
Description: This HIV-1 construct contains two distinct fluorescent proteins under control of
independent promotors. EGFP has been inserted in place of nef and is expressed through
LTR activation. An EF1a-mCherry transcriptional unit was inserted between EGFP and
the 3'LTR.
This construct can be used to study latent infection. The env is non-functional and nef
as been replaced with EGFP, so the construct can be used to produce single-cycle
infectious pseudotyped virions when combined with a suitable envelope expression
vector.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
References: Calvanese V, Chavez L, Laurent T, Ding S, Verdin E. Dual-color HIV reporters trace a
population of latently infected cells and enable their purification. Virology. 2013
Nov;446(1-2):283-92. ABSTRACT
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cat# 12595
DuoFluo (R7GEmC) from Drs. Vincenzo Calvanez and Eric Verdin."
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pNL-GFP-RRE(SA)
Catalog 11466
Number:
Release C
Category:
Description: pNL-GFP-RRE-(SA) is designed to express GFP in cells that express Rev and Tat. Thus, if
introduced into target cells through pseudotyping, it can detect HIV infected cells.
Cloning Vector: PUC18; The size of the insert is 7307bp. Size of vector and insert is 9669bp.
Special pNL-GFP-RRE was first constructed by complete deletion of all HIV ORFs of pNL4-3 by
Characteristics: replacing the 8.1 kb BssHII-BlpI fragment of the HIV-1 genomes with an insert containing
the GFP ORF and the HIV-1 RRE including the first 336 nucleotides of the gag ORF (the
gag reading frame was disrupted by a frame shift mutation at the ClaI site by blunt end
ligation). pNL-GFP-RRE-(SA) was constructed by insertion of a PCR fragment into the
NotI-SmaI site of pNL-GFP-RRE, in front of the GFP ORF. The insert carries the HIV-1 A5
splicing acceptor and D4 donor. GFP is expressed from the HIV-1 LTR promoter in HIV
infected cells when Tat and Rev are present.
GenBank EF408805
This reagent is currently being provided as purified DNA stabilized in DNAstable PLUS and
dried. Please see the notice for additional information and the protocol for reconstitution of
dried DNA reagents. Dried DNA Notice
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
References: Wu, Y. , Beddall, M.H. and Marsh, J.W. Rev-dependent lentiviral expression vector.
Retrovirology 4: 12 (2007). Abstract
NOTE: Acknowledgment for publications should read "The following reagent was obtained through
the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL-GFP-RRE(SA)(Cat#
11466) from Dr. Jon Marsh and Dr. Yuntao Wu." Also include the reference cited above in
any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pR7-GFP
Release D
Category:
Description: pR7-GFP expresses a modified green fluorescent protein (GFP), with the GFP coding
sequences substituted for HIV-1 Nef coding sequences.
Cloning Vector: SP65 modified to include an SV-gpt gene within the vector and an SV40 origin of
replication for amplification in T antigen-containing cells. Vector has an
ampicillin-resistance gene.
Special Alanine was substituted for serine at aa 65 in the modified jellyfish (Aequorea victoria)
Characteristics: GFP, resulting in markedly increased fluorescence as compared to wild type GFP. This
modification is similar to the traditional S65T modification used for EGFP.
Since there is a gpt gene in the plasmid but not in the provirus, infected cells cannot be
selected with any drug. Transfected cells can be selected with mycophenolic
acid/hypoxanthine/xanthine. The amount to use depends on the cell type. Selection
would ensure isolation of cells that have integrated the part of the construct that includes
the SV-gpt gene (in the vector), but does not ensure that an intact provirus is integrated.
One can easily screen selected clones for those that secrete virus by doing p24 assays on
the culture supernatant.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
References: Page KA, Liegler T, and Feinberg MA. Use of a green fluorescent protein as a marker for
human immunodeficiency virus type I infection. AIDS Res Hum Retroviruses
13:1077-1081, 1997.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pR7-GFP from
Drs. Kathleen Page, Teri Liegler, and Mark Feinberg". Also include the reference cited
above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pNL-r-HSAS
Release E
Category:
Special A 267 bp fragment from the ORF of HSA was inserted into an introduced XbaI site (nt
Characteristics: 5625) and an existing EcoRI site (nt 5743) of pNL4-3. This site is within the NL4-3 vpr
gene, which was paritally deleted during the digests. In addition, the start of vpr and two
potential start sites in the 3' end of vif are silenced by site-specific mutagenesis. The
insert was cloned in the 5'-3' orientation. The murine HSA insert was derived from the
plasmid pSL87c4-1. The insert contains the HSA ORF and 36 extraneous bases from the
original plasmid. HSA expression is driven by the HIV-1 LTR.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. Production of
acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells
transfected with an infectious molecular clone. J Virol 59:284-291, 1986.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL-r-HSAS from
Drs. Beth Jamieson and Jerome Zack." Also include the references cited above in any
publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Catalog 3417
Number:
Release C
Category:
Description: Two frameshifts render this NL4-3 clone Env- and Vpr-. When cotransfected with an Env
expression vector it will produce infectious virus that is competent for a single round of
infection.
Special The murine heat stable antigen CD24 (HSA) gene was inserted into the pNL4-3 nef gene
Characteristics: to produce this clone. Virus can be produced by transfecting 2 X 10 6 293 or 293T cells
with 10 μg NL4-3 DNA and 10 μg env expression vector DNA. Transfections can be
performed in a 10 cm 2 tissue culture dish using standard calcium phosphate protocols.
Virus is typically harvested 48 hours post-transfection. Infections should be performed in
a total volume of 0.5 ml. The amphotropic pseudotypes generally have much higher
infectivity than those bearing HIV-1 env. Cultures infected with HSA viruses can be
assayed by FACS analysis with a commercial CD24 antibody (Pharmingen) 2-5 days
post-infection.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable Plus.
Please see the notice for additional information and the protocol for reconstitution of dried
DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
References: He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency
virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting
p34cdc2 activity. J Virol 69:6705-6711, 1995. Connor RI, Chen BK, Choe S, Landau NR.
Vpr is required for efficient replication of human immunodeficiency virus type-1 in
mononuclear phagocytes. Virology 206:935-944, 1995.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1
pNL4-3.HSA.R - .E- from Dr. Nathaniel Landau." Also include the references cited above in
any publications. Patent pending.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: pNL4-3.HSA.R +
Catalog 3419
Number:
Release C
Category:
Provided: 5 μg of dried purified DNA stabilized in DNAstable PLUS
Description: Encodes replication competent NL4-3 proviral DNA.
Special This construct is 14,971 bp including the insert.
Characteristics:
Murine heat stable antigen CD24 (HSA) gene was inserted into the pNL4-3 (cat# 114) nef
gene to produce this clone. Virus can be produced by transfecting 2 X 10 6 293 or 293T
cells with 20 μg NL4-3 DNA. Transfections can be performed in a 10 cm2 tissue culture
dish using standard calcium phosphate protocols. Virus is typically harvested 48 hours
post-transfection. Infections should be performed in a total volume of 0.5 ml. The
amphotropic pseudotypes generally have much higher infectivity than those bearing HIV-1
env. Cultures infected with HSA viruses can be assayed by FACS analysis with a
commercial CD24 antibody (Pharmingen) 2-5 days post-infection.
GenBank Accession Number: pNL4-3: M19921
Contributor provided plasmid map information
Plasmid map and sequence file lot 150187
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
REV: 10/20/2019 Page 1 of 2
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
Contributor: Dr. Nathaniel Landau, Aaron Diamond AIDS Research Center, The Rockefeller University.
References: He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency
virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting
p34cdc2 activity. J Virol 69:6705-6711, 1995.
Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human
immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944, 1995.
NOTE: Acknowledgment for publications should read “The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3.HSA.R+
(cat# 3419) from Dr. Nathaniel Landau.” Also include the references cited above in any
publications.
Patent pending. Requests from commercial organizations must be directed to the
New York University Office of Industrial Liaison at the following email address:
sadhana.chitale@nyumc.org.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
REV: 10/20/2019 Page 2 of 2
DATA SHEET
Reagent: pNL4-3.HSA.R -
Catalog 3421
Number:
Release C
Category:
Provided: 5 μg of dried purified DNA stabilized in DNAstable PLUS
Description: Replication competent proviral DNA. Vpr- due to a frameshift at Vpr aa 26.
Special This construct is 14,975 bp including the insert.
Characteristics:
Murine heat stable antigen CD24 (HSA) gene was inserted into the pNL4-3 nef gene to
produce this clone. Virus can be produced by transfecting 2 X 10 6 293 or 293T cells with
20 μg NL4-3 DNA. Transfections can be performed in a 10 cm2 tissue culture dish using
standard calcium phosphate protocols. Virus is typically harvested 48 hours
post-transfection. Infections should be performed in a total volume of 0.5 ml. The
amphotropic pseudotypes generally have much higher infectivity than those bearing HIV-1
env. Cultures infected with HSA viruses can be assayed by FACS analysis with a
commercial CD24 antibody (Pharmingen) 2-5 days post-infection.
Contributor provided plasmid map
Plasmid map and sequence file lot 110077
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
REV: 10/20/2019 Page 1 of 2
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
Contributor: Dr. Nathaniel Landau, Aaron Diamond AIDS Research Center, The Rockefeller University.
References: He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency
virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting
p34cdc2 activity. J Virol 69:6705-6711, 1995.
Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human
immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944, 1995.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3.HSA.R-
from Dr. Nathaniel Landau." Also include the references cited above in any publications.
Patent pending. Requests from commercial organizations must be directed to the
New York University Office of Industrial Liaison at the following email address:
sadhana.chitale@nyumc.org.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
REV: 10/20/2019 Page 2 of 2
DATA SHEET
Release Category: C
Description: Env- due to a 5′ frameshift. Murine heat stable antigen CD24 (HSA) gene was inserted
into the pNL4-3 nef gene.
Ampicillin resistant
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for
reconstitution of dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture
Storage: barrier bag.
Contributor: Dr. Nathaniel Landau, Aaron Diamond AIDS Research Center, The Rockefeller
University.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of
human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:
935–944, 1995.Abstract
NOTE: Acknowledgment for publications should read “The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH:
pNL4-3.HSA.R+E-from Dr. Nathaniel Landau.” Also include the references cited above
in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release C
Category:
Description: A HIV-1 NL4-3 luciferase reporter vector that contains defective Nef, Env and Vpr.
Ampicillin resistant
To generate this plasmid, a frameshift near the 5'-end of env was introduced by using T4
DNA polymerase to fill in the NdeI site (nt 5950) of pNL4-3. This renders the clone Env
deficient. A firefly luciferase gene was then inserted into the nef gene by removing the
BamHI (nt 8021) to XhoI (nt 8443) fragment of pHXB-Luc (Chen et al. 1994) and
ligating it to the same sites in env deficient pNL4-3. A frameshift was introduced in vpr
by filling in the AflII site (nt 5180) corresponding to amino acid 26.
This construct is competent for a single round of replication and requires co-transfection
with an Env expression vector to produce infectious virus.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for reconstitution
of dried DNA reagents. Dried DNA Notice
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
References: Connor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995). Vpr is required for efficient
replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology,
206(2), 935-944. doi: 10.1006/viro.1995.1016 PUBMED
He, J., Choe, S., Walker, R., Di Marzio, P., Morgan, D. O., & Landau, N. R. (1995).
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase
of the cell cycle by inhibiting p34cdc2 activity. J Virol, 69(11), 6705-6711. PUBMED
Chen, B. K., Saksela, K., Andino, R., & Baltimore, D. (1994). Distinct modes of human
immunodeficiency virus type 1 proviral latency revealed by superinfection of
nonproductively infected cell lines with recombinant luciferase-encoding viruses. J Virol,
68(2), 654-660. PUBMED
NOTE: Acknowledgment for publications should read “The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 pNL4-3
ΔEnv Vpr Luciferase Reporter Vector (pNL4-3.Luc.R-E-) from Dr. Nathaniel Landau.” Also
include the references cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: A
Description of The plasmid contains all of the U3 region and approximately 75 bp of the R region,
Clone: including the TAR region the HIV-1 3' LTR driving the E. coli lacZ gene.
Special Standard β-galactosidase assays show quite high levels of expression in human
Characteristics: embryonic teratocarcinoma cells or activated monocyte-macrophage lines. Contains no
BamHI site. Digestion of this plasmid with KpnI can produce unusual cleavage patterns
(star activity) if buffer conditions are not correct, enzyme concentration is too high, or
the digest is done on a miniprep. When performing a mini-prep, use Asp718
(Boehringer-Mannheim Biochemicals) instead of KpnI.
Bacterial Host: HB101
Cloning Strategy: 3.2 kb lacZ gene from pCH110 was removed by digestion with
HindIII-BamHI and inserted in place of the pUR3III-CAT CAT gene.
Recommended -70°C.
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LTR lacZ
Reporter Vector (pHIVlacZ) from Dr. Joseph Maio (cat# 151)." Also include the reference
cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: B
Description: This construct bears the 3' LTR region from an HIV-1 subtype A patient isolate
upstream of the luciferase gene. The LTR was shown to be functional using the subtype
B LAI tat protein.
Cloning Vector: pBluescript KS(+). Ampicillin resistant. The construct size is 5721 bp.
Special The LTR region (nt -147 to +63 relative to the transcription start site) from a subtype
Characteristics: A patient isolate was PCR-amplified and exchanged into pBlue3'LTR-luc-B (Catalog
#4788) in place of the LAI LTR. It contains two NF-kB enhancers, three Sp1 binding
sites, the TATA box, and the TAR TNA hairpin motif.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for
reconstitution of dried DNA reagents. Dried DNA Notice
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
Klave B, Berkhout B. Comparison of the 5' and 3' LTR promoter function in the human
immunodeficiency virus. J Virol 68:3830-3840, 1994. Abstract
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 93UG66
LTR Luciferase Reporter Vector from Dr. Reink Jeeninga and Dr. Ben Berkhout (cat#
4787)." Also include the references cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: B
Description: This construct bears the 3' LTR region from an HIV-1 subtype C patient isolate
upstream of the luciferase gene. The LTR was shown to be functional using the subtype
B LAI tat protein.
Cloning Vector: pBluescript KS(+). Ampicillin resistant. The construct size is 5720 bp.
Special The LTR region (nt -147 to +63 relative to the transcription start site) from a subtype
Characteristics: C patient isolate was PCR-amplified and exchanged into pBlue3'LTR-luc-B (Catalog
#4788) in place of the LAI LTR. It contains two NF-kB enhancers, three Sp1 binding
sites, the TATA box, and the TAR TNA hairpin motif.
Recommended -70ºC.
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Klave B, Berkhout B. Comparison of the 5' and 3' LTR promoter function in the human
immunodeficiency virus. J Virol 68:3830-3840, 1994.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 93ZM74
LTR Luciferase Reporter Vector from Dr. Reink Jeeninga and Dr. Ben Berkhout (cat#
4789)." Also include the references cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: B
Description: This construct bears the 3' LTR region from an HIV-1 subtype D patient isolate
upstream of the luciferase gene. The LTR was shown to be functional using the subtype
B LAI tat protein.
Cloning Vector: pBluescript KS(+). Ampicillin resistant. The construct size is 5720 bp.
Special The LTR region (nt -147 to +63 relative to the transcription start site) from a subtype
Characteristics: D patient isolate was PCR-amplified and exchanged into pBlue3'LTR-luc-B (Catalog
#4788) in place of the LAI LTR. It contains two NF-kB enhancers, three Sp1 binding
sites, the TATA box, and the TAR TNA hairpin motif.
Recommended -70°C
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Klave B, Berkhout B. Comparison of the 5' and 3' LTR promoter function in the human
immunodeficiency virus. J Virol 68:3830-3840, 1994. Abstract
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 94ZR80
LTR Luciferase Reporter Vector from Dr. Reink Jeeninga and Dr. Ben Berkhout (cat#
4790)." Also include the reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: B
Description: This construct bears the 3' LTR region from an HIV-1 subtype E patient isolate
upstream of the luciferase gene. The LTR was shown to be functional using the subtype
B LAI tat protein.
Cloning Vector: pBluescript KS(+). Ampicillin resistant. The construct size is 5720 bp.
Special The LTR region (nt -147 to +63 relative to the transcription start site) from a subtype
Characteristics: E patient isolate was PCR-amplified and exchanged into pBlue3'LTR-luc-B (Catalog
#4788) in place of the LAI LTR. It contains two NF-kB enhancers, three Sp1 binding
sites, the TAAA box, and the TAR TNA hairpin motif.
Recommended -70°C
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Klave B, Berkhout B. Comparison of the 5' and 3' LTR promoter function in the human
immunodeficiency virus. J Virol 68:3830-3840, 1994. Abstract
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 97TH87
LTR Luciferase Reporter Vector from Dr. Reink Jeeninga and Dr. Ben Berkhout (cat#
4791)." Also include the reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: B
Description: This construct bears the 3' LTR region from an HIV-1 subtype F patient isolate
upstream of the luciferase gene. The LTR was shown to be functional using the subtype
B LAI tat protein.
Cloning Vector: pBluescript KS(+). Ampicillin resistant. The construct size is 5720 bp.
Special The LTR region (nt -147 to +63 relative to the transcription start site) from a subtype
Characteristics: F patient isolate was PCR-amplified and exchanged into pBlue3'LTR-luc-B (Catalog
#4788) in place of the LAI LTR. It contains two NF-kB enhancers, three Sp1 binding
sites, the TATA box, and the TAR TNA hairpin motif.
Recommended -70°C
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Klave B, Berkhout B. Comparison of the 5' and 3' LTR promoter function in the human
immunodeficiency virus. J Virol 68:3830-3840, 1994. Abstract
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 94BR77
LTR Luciferase Reporter Vector from Dr. Reink Jeeninga and Dr. Ben Berkhout (cat#
4792)." Also include the reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: B
Description: This construct bears the 3' LTR region from an HIV-1 subtype G patient isolate
upstream of the luciferase gene. The LTR was shown to be functional using the subtype
B LAI tat protein.
Cloning Vector: pBluescript KS(+). Ampicillin resistant. The construct size is 5720 bp.
Special The LTR region (nt -147 to +63 relative to the transcription start site) from a subtype
Characteristics: G patient isolate was PCR-amplified and exchanged into pBlue3'LTR-luc-B (Catalog
#4788) in place of the LAI LTR. It contains two NF-kB enhancers, three Sp1 binding
sites, the TATA box, and the TAR TNA hairpin motif.
Recommended -70°C
Storage:
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Klave B, Berkhout B. Comparison of the 5' and 3' LTR promoter function in the human
immunodeficiency virus. J Virol 68:3830-3840, 1994. Abstract
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 CB76 LTR
Luciferase Reporter Vector from Dr. Reink Jeeninga and Dr. Ben Berkhout (cat# 4793)."
Also include the reference cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Reagent: HIV-1 YU2 NanoLuc Reporter Vector (prRosa26 CMV-IE NLuc Env)
Release C
Category:
Ampicillin resistant
The final 1500 nucleotides of gag and the leading 2306 nucleotides of the pol region of
YU2 were replaced with a loxP site and the coding region for Nanoluciferase. The entire
proviral sequence was then transferred into a backbone containing sequences
homologous to 1021 nucleotides upstream and 998 nucleotides downstream of the
Rosa26-targeted CRISPR-induced breakpoint. The provirus was then modified further by
replacing the LTR with the CMV-IE promoter via ligation independent cloning.
Plasmids can be propagated in STBL2 cells and grown at 37°C. Larger plasmids may
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
Plus. Please see the notice for additional information and the protocol for reconstitution of
dried DNA reagents. Dried DNA Notice
Recommended Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier
Storage: bag.
NOTE: Acknowledgement for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 YU2
NanoLuc Reporter Vector (prRosa26 CMV-IE NLuc Env) from Dr. Brandon Harvey (cat#
13119)."
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: B
Description: This construct bears the LAI 3' LTR upstream of the luciferase gene. The LTR was shown
to be functional using the subtype B LAI tat protein.
Special Contains a 1426 bp BglI-XhoI fragment from pBluescript KS(+) with the ColE1 origin, a
Characteristics: 719 bp XhoI-HindIII LAI 3' LTR fragment, a 1951 bp HindIII-BamHI pGL3 luciferase
gene, and a 1625 bp BamHI-BglI fragment derived from pSV2CAT, which encompasses
an SV40 polyA site and a pBluescript KS(+) fragment. The construct size is 5720 bp.
This reagent is currently being provided as dried purified DNA stabilized in DNAstable
PLUS. Please see the notice for additional information and the protocol for
reconstitution of dried DNA reagents. Dried DNA Notice
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Klave B, Berkhout B. Comparison of the 5' and 3' LTR promoter function in the human
immunodeficiency virus. J Virol 68:3830-3840, 1994.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LAI LTR
Luciferase Reporter Vector from Dr. Reink Jeeninga and Dr. Ben Berkhout (cat# 4788)."
Also include the references cited above in any publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release C
Category:
Description: Infectious molecular clone of HIV-1HXB2. The human placental alkaline phosphatase
(PLAP) gene has been inserted into the nef open reading frame. The nef open reading
frame has been disrupted by the introduction of a frame shift mutation at a unique XhoI
site in the nef coding region.
Special Produces high titer infectious HIV-1 when transfected into 293T cells. Virus carries the
Characteristics: PLAP reporter gene into target cells. Quantitative analysis of infection on a single cell level
can be done by histochemical staining for phosphatase activity or by flow cytometry with
anti-PLAP antibodies. Serves as a nef-deficient control for pHXBnPLAP-IRES-N+ (Catalog
#3610). When both clones are used in parallel experiments, the effects of Nef on
expression of cell surface molecules such as CD4 may be directly examined during acute
infection.
Recommended -70°C.
Storage:
References: Chen BK, Gandhi R, Baltimore D. CD4 down-modulation during infection of human T cells
with human immunodeficiency virus type 1 involves independent activities of vpu, env,
and nef. J Virol 70:6044-6053, 1996.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Release Category: C
Description: Infectious molecular clone of HIV-1 HXB2 with the human placental alkaline
phosphatase (PLAP) gene inserted into the nef open reading frame. This plasmid
expresses functional HXB2 nef and vpu.
Expression of a functional HXB2 nef allele has been restored by insertion of an internal
ribosomal entry site from the encephalomyocarditis (ECMV) and repairing the nef open
reading frame.
Expression of a functional HXB2 vpu allele has been restored by repairing a premature
stop codon present in the HXB2 parent clone used to construct Cat# 3610
pHXBnPLAP-IRES-N+U-.
This reagent is currently being provided as purified DNA stabilized in DNAstable PLUS
and dried. Please see the notice for additional information and the protocol for
reconstitution of dried DNA reagents. Dried DNA Notice
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
References: Chen BK, Gandhi R, Baltimore D. CD4 down-modulation during infection of human T
cells with human immunodeficiency virus type 1 involves independent activities of vpu,
env, and nef. J Virol 70:6044–6053, 1996.
NOTE: Acknowledgment for publications should read "The following reagent was obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 HXB2
ALPP Reporter Vector (pHXBnPLAP-IRES-N+U+) from Dr. Benjamin K. Chen and Dr.
David Baltimore (cat# 12750)." Also include the reference cited above in any
publications.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL,
AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT,
FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.